It seems most drug-makers are making their biggest sales to doctors by pushing medicines for common conditions whether they be statins for cholesterol or proton pump inhibitors for heartburn. But drugs can actually take on blockbuster significance for specialized treatment groups where treatment options are limited. Jeffrey Aronin, president and CEO of Ovation Pharmaceuticals Inc. tells the Chicago Tribune's Bruce Japsen about his company's efforts to build blockbuster franchises by treating rare conditions.
